Biopharma AI
By
Can Novo Nordisk and Fangzhou’s AI-Powered Partnership Reshape Chronic Disease Care in China’s Digital Health Boom?
Key Insights: Revolutionizing Chronic Disease ManagementChina faces one of the world’s highest burdens of chronic diseases, particularly diabetes…
Can Absci’s AI-Powered Drug Platform Disrupt $600M+ Biopharma Pipelines by 2026?
Absci blends AI and biology—end-to-endUnlike other AI drug startups that rely on outsourcing, Absci integrates generative AI with…
Can Chugai (Roche subsidiary) and Gero’s $250M AI-Driven Alliance Unlock a New Era in Anti-Aging Therapies?
Key Takeaways: AI-Powered Target Discovery Meets World-Class Antibody EngineeringThe joint research and license agreement between Tokyo-based Chugai Pharmaceutical…
Could AbbVie and IGI’s $1.9B Bet on AI-Engineered Trispecific Antibody Signal a New Era for Relapsed Myeloma Treatment?
Key Highlights: AbbVie Accelerates into AI-Powered Immuno-OncologyAbbVie has entered a global licensing agreement worth up to $1.925 billion…
Will AI-Powered Querent™ by Mango Sciences Transform Veeda Lifesciences’ Global Clinical Trial Efficiency?
Key Highlights AI-Driven Precision in Global Trial RecruitmentVeeda Lifesciences, a global CRO, has announced a strategic investment in…
Can Revolution Medicines and Iambic’s AI Alliance Accelerate the Discovery of Next-Gen Cancer Drugs Targeting RAS Mutations?
Key Highlights AI-Powered Discovery for RAS-Addicted CancersRevolution Medicines, a leader in targeting RAS-driven cancers, is turning to artificial…
Can Johnson & Johnson’s 6-Point AI Strategy Revolutionize Surgery, Drug Discovery, and Global Patient Care?
Key Highlights From Experimentation to Execution: Focused AI for Measurable OutcomesAfter piloting 900+ generative AI use cases, Johnson…
At VivaTech 2025, Can NVIDIA, Sanofi, and TetraScience Unlock the Full Potential of Scientific AI Despite a 20-Exabyte Data Barrier?
Key Highlights The 20-Exabyte Problem: Data, Not Models, Is the Limiting FactorAt The Rise of Scientific AI panel…
Is AstraZeneca’s $20M AI Hub in Bengaluru the Catalyst for 20 New Medicines by 2030?
Key Highlights Strategic Investment to Scale AI-Driven InnovationAstraZeneca has inaugurated a state-of-the-art Global Hub in Bengaluru with an…
Can Lisata Therapeutics and GATC Health’s AI Breakthrough Redefine Drug Discovery and Tackle the Opioid Crisis in Just One Year?
Key Highlights AI-Powered Drug Discovery Moves Toward the Clinic with OUD FocusLisata Therapeutics and GATC Health have expanded…
Is Merck’s $10B Acquisition of Verona a Strategic Masterstroke to Offset Keytruda’s Patent Cliff and Dominate the $30B+ Respiratory Market?
Key Highlights Merck Secures Verona to Bridge Its Post-Keytruda Future Merck & Co. has taken a bold step…
Can Google DeepMind’s Isomorphic Labs Revolutionize Clinical Trials with AI-Designed Drugs Backed by $600M and AlphaFold Breakthrough?
Key Takeaways AI to Clinic: Isomorphic Labs Moves Beyond Design to Human TrialsIsomorphic Labs, the AI drug discovery…
Five Breakthrough AI Innovations Set to Transform Healthcare in 2025
The healthcare industry is poised for a major transformation in 2025 as artificial intelligence (AI) technologies continue to…
Biomni AI Agent Unveils New Era in Biology Research with Claude 4 Sonnet Integration and Extensive Toolset
A groundbreaking advancement in life sciences research has arrived with the launch of Biomni, a state-of-the-art AI agent…
Is NVIDIA’s 2025 Healthcare AI Report the Tipping Point for 80% of Providers and Pharma to Redefine Efficiency and Innovation?
Key Highlights Healthcare Sees Rapid ROI with Generative AIAccording to NVIDIA’s 2025 State of AI in Healthcare and…
Could Everest Medicines’ AI-Powered mRNA Platform Signal a Turning Point for Cancer and Autoimmune Therapies in Asia?
Key Highlights Reimagining Cancer Vaccines with AI-Optimized PersonalizationAt the 2025 Everest Medicines R&D Day, the company showcased EVM16,…
Shift Bioscience Unveils AI Framework to Improve Gene Target Discovery for Rejuvenation Therapies
Key Highlights Deeper DiveCambridge-based Shift Bioscience is rethinking how AI models are evaluated for rejuvenation research. Their study,…
Can Syntis Bio’s $38M Series A Transform Oral Biologics for Obesity and Rare Diseases?
Key Highlights Funding to Advance Novel Oral TherapiesBoston-based Syntis Bio announced the close of its $38 million financing…
